Ultragenyx (RARE)

42.37 -1.01 (-2.33%)
Closed USD Disclaimer
42.37 0.00 (0.00%)

Ultragenyx Company Profile

Equity Type
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company's clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Contact Information
Novato,94949 United States
415 483 8800
Top Executives
Daniel G. Welch 63 2015 Independent Non-Executive Chairman
Michael A. Narachi 62 2015 Independent Director
Matthew K. Fust 56 2013 Independent Director
Shehnaaz Suliman 51 2019 Independent Director
Emil D. Kakkis 62 2010 Founder, President, CEO & Director
Deborah Dunsire 62 2017 Independent Director
Amrit Ray 50 2022 Independent Director
Corazon Dating Sanders 67 2021 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.